Prof. PeptideProf. Peptide
Guide

CagriSema Dosage in 2026: Trial Doses and What Clinics Report

CagriSema is Novo Nordisk's investigational once-weekly combination of cagrilintide, an amylin analog, with semaglutide. Its peer-reviewed phase 3 weight trials gave 2,400 mcg (2.4 mg) of each once weekly after a 16-week build-up [1][2][3]; clinics describe that trial schedule rather than a dose of their own [9][10]. It is not approved anywhere.

No approved dose

CagriSema has no prescribing information yet. The doses below are what its trials administered and what clinics report, as their sources state them.

How is CagriSema dosed?

CagriSema is dosed once weekly by subcutaneous injection: clinics describe the trial schedule, a 16-week build-up every 4 weeks from 250 mcg to 2,400 mcg (2.4 mg), as Wegovy's, then 2,400 mcg (2.4 mg) of each drug weekly from one pen [10]. No trial has set a dose for use outside a study.

  • Clinics: no clinic was found prescribing CagriSema after searching 13 clinic sources, the eight largest telehealth companies among them [9][10][14]. Clinics describe the trial schedule, given for context rather than as an instruction [10].
  • Why the build-up: clinics say the dose is raised slowly to limit side effects, and that combining two appetite drugs can mean more of them [10][14].
  • Maintenance in the trials: 2,400 mcg + 2,400 mcg (2.4 mg + 2.4 mg) weekly in the weight trials [1][2][3]; the type 2 diabetes trials also tested 1,000 mcg + 1,000 mcg (1.0 mg + 1.0 mg) [4][5][6].
  • No clinic publishes a maximum dose or course length of its own.

Side effects are under What are the side effects of CagriSema?, its status under Is CagriSema legal?, and each trial’s doses under What do human studies show about CagriSema dosing? Cagrilintide on its own is covered in cagrilintide dosage.

How is CagriSema taken?

CagriSema was administered by subcutaneous injection once weekly in every trial, with both components given together [1][2][3]; clinics describe a single prefilled pen [10]. No human data exist for any other route, and no approved label yet sets out how it is injected or stored, so neither is described beyond what the trials and clinics report.

What are the side effects of CagriSema?

CagriSema's most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, constipation and abdominal pain: 79.6% vs 39.9% on placebo in REDEFINE 1 and 72.5% vs 34.4% in REDEFINE 2, mostly transient and mild to moderate [1][2]. No label yet lists its warnings or contraindications.

  • Against semaglutide alone: adverse events in 87% vs 84%, gastrointestinal in 53% vs 51%; 10% vs 6% discontinued (REDEFINE 5) [3].
  • Type 2 diabetes: adverse events in 86.9% on CagriSema vs 81.2% on semaglutide 2,400 mcg (2.4 mg) and 70.5% on placebo, most often gastrointestinal (REIMAGINE 2) [5].
  • On basal insulin: no severe hypoglycemia; one death, from cancer, judged unrelated (REIMAGINE 3) [6].

What clinics report

Clinics describe side effects similar to semaglutide's, mostly gastrointestinal and early, while the dose is being raised [9][10]; they list nausea, constipation, diarrhea and vomiting, usually mild to moderate and strongest early [14]. No clinic reports its own patients' experience.

What do human studies show about CagriSema dosing?

CagriSema's doses have been tested in six peer-reviewed phase 3 trials: REDEFINE 1, 2 and 5 in weight management at 2,400 mcg + 2,400 mcg (2.4 mg + 2.4 mg) weekly [1][2][3], and REIMAGINE 1, 2 and 3 in type 2 diabetes, which also tested 1,000 mcg (1 mg) of each [4][5][6], after a phase 2 and a phase 1b trial [7][8].

Novo Nordisk, which develops CagriSema, funded the REIMAGINE trials [4][5][6].

REDEFINE 1 — overweight or obesity

N Engl J Med 2025 [1]

Doses: Cagrilintide 2,400 mcg (2.4 mg) with semaglutide 2,400 mcg (2.4 mg) once weekly vs placebo for 68 weeks, with lifestyle intervention [1].

Result: Weight change −20.4% vs −3.0% on placebo [1]; in a secondary and post hoc analysis, systolic blood pressure −10.9 vs −2.8 mm Hg [11].

Safety: Gastrointestinal adverse events, including nausea, vomiting, diarrhea, constipation and abdominal pain, in 79.6% vs 39.9%, mostly transient and mild to moderate [1].

REDEFINE 2 — obesity with type 2 diabetes

N Engl J Med 2025 [2]

Doses: The same 2,400 mcg + 2,400 mcg (2.4 mg + 2.4 mg) weekly dose vs placebo for 68 weeks [2].

Result: Weight change −13.7% vs −3.4% on placebo [2].

Safety: Gastrointestinal adverse events in 72.5% vs 34.4% [2].

REDEFINE 5 — against semaglutide alone

Lancet Diabetes Endocrinol 2025 [3]

Doses: CagriSema 2,400 mcg + 2,400 mcg (2.4 mg + 2.4 mg) vs semaglutide 2,400 mcg (2.4 mg) alone, once weekly for 68 weeks [3].

Result: Weight change −18.4% vs −11.9% with semaglutide alone [3].

Safety: Adverse events in 87% vs 84%, gastrointestinal in 53% vs 51%; 10% vs 6% discontinued [3].

REIMAGINE 1 — early type 2 diabetes

Lancet Diabetes Endocrinol 2026 [4]

Doses: 189 adults on diet and exercise: 2,400 mcg + 2,400 mcg (2.4 mg each, n=62), 1,000 mcg + 1,000 mcg (1.0 mg each, n=63) or placebo (n=64) for 40 weeks [4].

Result: HbA1c −1.8 and −1.5 points at the higher and lower doses vs −0.1 on placebo [4].

Safety: Funded by Novo Nordisk, the developer [4].

REIMAGINE 2 — type 2 diabetes, against semaglutide

Lancet Diabetes Endocrinol 2026 [5]

Doses: 2,713 adults on metformin with or without an SGLT2 inhibitor: CagriSema at 2,400 mcg (2.4 mg) or 1,000 mcg (1 mg) of each, semaglutide 2,400 or 1,000 mcg (2.4 or 1 mg), cagrilintide 2,400 mcg (2.4 mg), or placebo, for 68 weeks [5].

Result: HbA1c −1.91 points with CagriSema 2,400 mcg + 2,400 mcg (2.4 mg + 2.4 mg) vs −1.75 with semaglutide 2,400 mcg (2.4 mg) [5].

Safety: Adverse events in 86.9% on CagriSema vs 81.2% on semaglutide 2,400 mcg (2.4 mg) and 70.5% on placebo, most often gastrointestinal [5].

REIMAGINE 3 — on basal insulin

Lancet 2026 [6]

Doses: 274 adults: 2,400 mcg + 2,400 mcg (2.4 mg + 2.4 mg; n=90), 1,000 mcg + 1,000 mcg (1 mg + 1 mg; n=93) or placebo (n=91) for 40 weeks [6].

Result: HbA1c −2.33 and −2.10 points vs −0.66 on placebo; body weight fell by 10% to 12% [6].

Safety: No severe hypoglycemia was reported; one death, from cancer, was judged unrelated to treatment [6].

Phase 2 and phase 1b

Lancet 2023 and 2021 [7][8]

Doses: Phase 2: cagrilintide 2,400 mcg (2.4 mg) with semaglutide 2,400 mcg (2.4 mg) weekly in 92 people with type 2 diabetes for 32 weeks [7]. Phase 1b: multiple doses in 96 adults [8].

Result: In the phase 1b trial, cagrilintide did not change semaglutide's exposure [8].

Safety: Phase 1b: 37% of 566 adverse events were gastrointestinal, most mild to moderate [8].

FAQ

What is the dosage of CagriSema?
CagriSema has no approved dose. Its phase 3 weight trials gave 2,400 mcg (2.4 mg) cagrilintide with 2,400 mcg (2.4 mg) semaglutide once weekly by subcutaneous injection, after a 16-week build-up; the type 2 diabetes trials also tested 1,000 mcg (1 mg) of each. Clinics describe the trial schedule rather than a dose of their own.
How is the CagriSema dose increased?
Clinics describe the trial schedule: a 16-week build-up in which the dose rises every 4 weeks from 250 mcg to 2,400 mcg (2.4 mg), the same steps as Wegovy's, then both drugs at 2,400 mcg (2.4 mg) once a week from one prefilled pen. The dose is raised slowly to limit side effects.
How much weight do people lose on CagriSema?
In REDEFINE 1, adults with overweight or obesity changed weight by −20.4% vs −3.0% on placebo over 68 weeks; with type 2 diabetes (REDEFINE 2), −13.7% vs −3.4%. Against semaglutide alone in REDEFINE 5, CagriSema reached −18.4% vs −11.9%. All three trials are peer-reviewed.
What are the side effects of CagriSema?
Mainly gastrointestinal, including nausea, vomiting, diarrhea, constipation and abdominal pain: 79.6% vs 39.9% on placebo in REDEFINE 1 and 72.5% vs 34.4% in REDEFINE 2, mostly transient and mild to moderate. Against semaglutide alone, 10% vs 6% stopped treatment in REDEFINE 5.
Is CagriSema FDA-approved?
No. CagriSema is investigational, and clinics state that it is not available for routine prescribing. FDA states that cagrilintide, one of its two components, cannot be used in compounding under federal law.

References

  1. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025. PMID 40544433. https://pubmed.ncbi.nlm.nih.gov/40544433/
  2. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med. 2025. PMID 40544432. https://pubmed.ncbi.nlm.nih.gov/40544432/
  3. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity (REDEFINE 5). Lancet Diabetes Endocrinol. 2025. PMID 42009015. https://pubmed.ncbi.nlm.nih.gov/42009015/
  4. Aroda VR, Buzzetti R, Dalskov SM, et al. Once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1). Lancet Diabetes Endocrinol. Published June 7, 2026. PMID 42251860. NCT06323174. https://pubmed.ncbi.nlm.nih.gov/42251860/
  5. Buse JB, Bajaj HS, Dalskov SM, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2). Lancet Diabetes Endocrinol. Published June 7, 2026. PMID 42251859. NCT06065540. https://pubmed.ncbi.nlm.nih.gov/42251859/
  6. Rosenstock J, Billings LK, Gajria R, et al. Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3). Lancet. Published June 7, 2026. PMID 42251856. NCT06323161. https://pubmed.ncbi.nlm.nih.gov/42251856/
  7. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a phase 2 trial. Lancet. 2023. PMID 37364590. https://pubmed.ncbi.nlm.nih.gov/37364590/
  8. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg: a phase 1b trial. Lancet. 2021;397:1736–48. PMID 33894838. https://pubmed.ncbi.nlm.nih.gov/33894838/
  9. Ro, CagriSema for weight loss. Read November 4, 2026. Cited for its status, availability and price statements. https://ro.co/weight-loss/cagrisema-for-weight-loss/
  10. Second Nature (UK), What is CagriSema? Read November 4, 2026. Cited for its description of the trial schedule and its status statement. https://www.secondnature.io/guides/weight-loss-medications/what-is-cagrisema
  11. Verma S, Böttcher M, Brown P, et al. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. Hypertension. Published December 2, 2025 (secondary and post hoc analysis). PMID 41328546. https://pubmed.ncbi.nlm.nih.gov/41328546/
  12. Superpower, CagriSema guide. Read November 4, 2026. Cited for its status statement. https://superpower.com/guides/peptides/cagrisema
  13. W8MD Medical Weight Loss, Philadelphia; status as of September 1, 2026. Read November 4, 2026. Cited for its status statement. https://philadelphiamedicalweightloss.com/cagrisema-philadelphia/
  14. Pru, cagrilintide vs semaglutide, updated July 9, 2026; read November 5, 2026. Cited for its side-effect and dose-escalation statements. https://joinpru.com/blog/cagrilintide-vs-semaglutide
  15. U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of October 1, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  16. World Anti-Doping Agency. The Prohibited List (2026). Valid January 1, 2026. https://www.wada-ama.org/en/prohibited-list

Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.

Checked and updated